menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Sobi`s FDA Acceptance of Avatrombopag NDA for Pediatric ITP

    GLOBENEWSWIRE

    Gyre Therapeutics Announces NMPA Approval Of Avatrombopag Maleate Tablets

    GLOBENEWSWIRE

    Health Canada Approves DOPTELET for Two Indications in Thrombocytopenia

    GLOBENEWSWIRE

    Doptelet® (avatrombopag) receives positive opinion from CHMP ITP

    PRNEWSWIRE

    Swedish Orphan`s avatrombopag flunks late-stage study in chemo-induced

    SEEKINGALPHA

    NICE pushes Doptelet for pre-surgery liver disease treatment

    PHARMA TIMES

    Dova Granted Orphan Drug Designation for Avatrombopag

    PR NEWSWIRE

    Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag)

    PR NEWSWIRE

    Sobi finds another fit for its dealmaking strategy

    BIOPHARMADIVE

    Can Dova take on Novartis? With its 2nd Doptelet nod and a price cut, maybe so

    FIERCE PHARMA

    Cosmo to give Bausch Health a run for its money with FDA nod for Xifaxan rival

    FIERCE PHARMA

    Dova picked up its newly approved drug castoff at a low price

    ENDPTS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.